Report of transactions in Zealand’s shares and related securities by executives and their related parties


Copenhagen, 2015-11-19 14:44 CET (GLOBE NEWSWIRE) -- 19 November 2015 Pursuant to the Danish Securities Trading Act, section 28a, Zealand must disclose information on transactions with the company’s shares and related securities by executives and persons/companies closely related to them.

With reference to the above, Zealand announces it has received information on the following transactions for disclosure:     

 

 

 

Name: Christian Thorkildsen
Reason: Employee elected member of the Board of Directors
Issuer: Zealand Pharma A/S
Designation: Shares
ISIN Code: DK0060257814
Transaction: Sale of shares
Trading Date: 17 November 2015
Market: Nasdaq Copenhagen
Number: 20,000
Price: DKK 147.17
Total value: DKK 2,943,400.00

 

 

 

 

Name: Helle Størum
Reason: Employee elected member of the Board of Directors
Issuer: Zealand Pharma A/S
Designation: Shares
ISIN Code: DK0060257814
Transaction: Sale of shares
Trading Date: 17 November 2015
Market: Nasdaq Copenhagen
Number: 1,000
Price: DKK 150.00
Total value: DKK 150,000.00

 

 

 

 

 

●●●●●

 

 

For further information, please contact:

Hanne Leth Hillman, Senior Vice President for Investor Relations and Communications

Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

 

 

 

About Zealand Pharma

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) is a biotech company with leading-edge scientific expertise in turning peptides into medicines. Zealand has a growing proprietary pipeline of novel specialty drug candidates and a mature portfolio of products and projects under license collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim.

Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of Type 2 diabetes, is marketed globally outside the US as Lyxumia® by Sanofi and under regulatory review in the US. The license collaboration with Sanofi covers also a single-product combination of lixisenatide and insulin glargine (Lantus®) which is on track for regulatory submission in the US in Q4 2015 and in the European Union in Q1 2016.

The proprietary pipeline includes; danegaptide for ischemic reperfusion Injuries in Phase II development; ZP1848 for Short Bowel Syndrome in Phase II development; and the stable glucagon analogue, ZP4207, in Phase II preparation both as a single-dose rescue pen for severe hypoglycemia and for multiple-dose use to treat and control mild to moderate hypoglycemia; as well as several preclinical peptide therapeutics.

The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand’s business and activities, please visit: www,zealandpharma.com or follow us on Twitter @ZealandPharma

 


Attachments

05-15_1119 - Report on transactions - ENG_final.pdf